raloxifene hydrochloride has been researched along with Invasiveness, Neoplasm in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, KM; Rosengren, RJ; Scandlyn, MJ; Taurin, S | 1 |
| Greish, K; Nehoff, H; Rosengren, RJ; Taurin, S; van Aswegen, T | 1 |
| Larsen, L; Nimick, M; Rosengren, RJ; Taurin, S | 1 |
| Flamini, MI; Neira, FJ; Sanchez, AM; Shortrede, JE; Uzair, ID | 1 |
| Jordan, VC | 2 |
| Barrett-Connor, E; Cauley, JA; Collins, P; Geiger, MJ; Grady, D; Kornitzer, M; Mershon, J; Mosca, L; Song, J; Wenger, NK | 1 |
| Keating, GM; Moen, MD | 1 |
| Flamini, MI; Fu, XD; Garibaldi, S; Genazzani, AR; Giretti, MS; Goglia, L; Pisaneschi, S; Sanchez, AM; Simoncini, T; Tosi, V | 1 |
| Hoshi, SL; Kondo, M; Toi, M | 1 |
| Atkins, JN; Bevers, TB; Cecchini, RS; Costantino, JP; Cronin, WM; Fehrenbacher, L; Ford, LG; Ganz, PA; James, J; Jordan, VC; Margolese, RG; McCaskill-Stevens, W; Pajon, ER; Reis, SE; Robidoux, A; Runowicz, CD; Vogel, VG; Wade, JL; Wickerham, DL; Wolmark, N | 1 |
| Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Land, SR; Weissfeld, JL; Wickerham, DL; Wolmark, N | 1 |
| Bandos, H; Cauley, JA; Cecchini, RS; Costantino, JP; Cronin, WM; Weissfeld, JL; Wickerham, DL; Wolmark, N | 1 |
| Costantino, JP; Cronin, WM; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Christopoulos, S; Rivera, JA; Small, D; Trifiro, M | 1 |
| Eng-Wong, J; Faupel-Badger, JM; Prindiville, SA; Venzon, D; Vonderhaar, BK; Zujewski, JA | 1 |
| Cauley, JA; Cummings, SR; Disch, DP; Dowsett, SA; Lippman, ME; Martino, S; Mershon, JL | 1 |
| Goldstein, SR | 1 |
4 review(s) available for raloxifene hydrochloride and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Raloxifene: a review of its use in the prevention of invasive breast cancer.
Topics: Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Quality of Life; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Brachial Plexus Neuropathies; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Gonadotropin-Releasing Hormone; Humans; Leiomyoma; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasms; Nitriles; Radiography, Thoracic; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Triazoles; Uterine Neoplasms | 2004 |
The science of selective estrogen receptor modulators: concept to clinical practice.
Topics: Breast Neoplasms; Female; Humans; Models, Biological; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Structure-Activity Relationship; Tamoxifen | 2006 |
The effect of SERMs on the endometrium.
Topics: Breast Neoplasms; Endometrial Neoplasms; Endometrium; Female; Humans; Neoplasm Invasiveness; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2001 |
4 trial(s) available for raloxifene hydrochloride and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.
Topics: Aged; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Incidence; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Osteoporosis, Postmenopausal; Proportional Hazards Models; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Spine | 2008 |
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Cataract; Double-Blind Method; Drug Utilization; Endometrial Neoplasms; Estrogens; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Incidence; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Tamoxifen; Thromboembolism; Uterus | 2010 |
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Topics: Adult; Aged; Anticarcinogenic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Patient Participation; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen | 2002 |
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Estradiol; Female; Humans; Middle Aged; Neoplasm Invasiveness; Pilot Projects; Premenopause; Prolactin; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin | 2006 |
11 other study(ies) available for raloxifene hydrochloride and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Movement; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Invasiveness; Raloxifene Hydrochloride; Receptors, Estrogen; Triple Negative Breast Neoplasms | 2013 |
A novel role for raloxifene nanomicelles in management of castrate resistant prostate cancer.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA, Neoplasm; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Male; Maleates; Matrix Metalloproteinase 9; Micelles; Nanoparticles; Necrosis; Neoplasm Invasiveness; Polystyrenes; Prostatic Neoplasms, Castration-Resistant; Protein Biosynthesis; Raloxifene Hydrochloride; Receptors, Estrogen; Spheroids, Cellular | 2014 |
A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines.
Topics: Apoptosis; Breast Neoplasms; Caspase 3; Cell Line, Tumor; Cell Movement; Curcumin; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Neoplasm Invasiveness; Raloxifene Hydrochloride; Receptors, Estrogen; Signal Transduction | 2016 |
Paxillin, a novel controller in the signaling of estrogen to FAK/N-WASP/Arp2/3 complex in breast cancer cells.
Topics: Actin Cytoskeleton; Actin-Related Protein 2-3 Complex; Breast Neoplasms; cdc42 GTP-Binding Protein; Cell Adhesion; Cell Line, Tumor; Cell Movement; Estrogen Receptor alpha; Estrogens; Female; Focal Adhesion Protein-Tyrosine Kinases; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein beta Subunits; Humans; Neoplasm Invasiveness; Paxillin; Phosphorylation; Protein Transport; Raloxifene Hydrochloride; Signal Transduction; src-Family Kinases; Wiskott-Aldrich Syndrome Protein, Neuronal | 2016 |
The rise of raloxifene and the fall of invasive breast cancer.
Topics: Aged; Animals; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Evidence-Based Medicine; Female; Humans; Incidence; Middle Aged; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2008 |
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton.
Topics: Actins; Breast Neoplasms; Cell Line, Tumor; Cytoskeleton; Female; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Raloxifene Hydrochloride | 2009 |
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Cost-Benefit Analysis; Female; Humans; Japan; Markov Chains; Middle Aged; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen | 2009 |
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
Topics: Adult; Aged; Body Mass Index; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Invasiveness; Obesity; Postmenopause; Premenopause; Proportional Hazards Models; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk; Tamoxifen | 2012 |
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma; Cell Count; Combined Modality Therapy; Female; Humans; Mammography; Middle Aged; Neoplasm Invasiveness; Postmenopause; Predictive Value of Tests; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen | 2012 |
Raloxifene (Evista) for breast cancer prevention in postmenopausal women.
Topics: Breast Neoplasms; Female; Humans; Incidence; Neoplasm Invasiveness; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2006 |
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Topics: Aged; Breast Neoplasms; Female; Follow-Up Studies; Humans; Incidence; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Osteoporosis, Postmenopausal; Placebos; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2006 |